The FibroScan-AST (FAST) score has been shown to be effective for the risk assessment of non-alcoholic hepatic steatosis (NASH) in patients without HIV, but its effectiveness in HIV+ patients is currently...
In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
A new study presented at CROI 2019 explored whether switching to monthly long-acting CAB+RPV is noninferior to continuing current 3-drug oral ART in adults with virologically suppressed HIV-1 infection.
...
